NASDAQIDYA

Ideaya Biosciences (NASDAQ:IDYA) shares jumped as much as 23% premarket on Monday after the oncology company reported positive interim data from an expansion dose cohort of a mid-stage trial of IDE397. IDE397 is a potential first-in-class MAT2A (methionine adenosyltransferase 2 alpha) inhibitor, that is being advanced as a monotherapy agentContinue Reading